All In MedTech

FDA Clearance Tracker · P230040-S015

CorPASS System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 19, 2025

Approved

Time to decision

231 days

Received May 2, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P230040-S015
Device name
CorPASS System
Applicant location
Naperville, IL
Received
May 2, 2025
Decided
Dec 19, 2025
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P230040

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code MOM

FDA's approval statement

As written in FDA's record.

Approval for to modifications in the implanter’s labeling to remove the mandatory Sensor recalibrations every 3 years.

Source documents

Other decisions for Endotronix, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.